What are the side effects of fezolinetant?

Fezolinetant is a novel neurokinin 3 (NK3) receptor antagonist primarily used to relieve moderate to severe vasomotor symptoms associated with menopause. As a non-hormonal drug, fezonatant provides a new alternative to traditional hormone replacement therapy. Although it has shown good efficacy and mild side effects in clinical trials, as with any drug, the use of felazonatant may still be associated with some side effects.

The side effects of filzonitant are generally mild and, in most cases, tolerated by patients during treatment. According to clinical studies and drug inserts, the most common side effects include headache, nausea, dry mouth and abdominal discomfort. Most of these side effects are temporary and will gradually lessen as the body adjusts to the medication.

Some patients may experience symptoms of digestive discomfort, such as diarrhea, constipation, or stomach bloating. These problems are usually mild and uncommon, but patients need to pay attention to the reaction of their digestive system while taking fezonatant, especially during the early stages of starting the drug. If symptoms are severe or persistent, it is recommended to seek medical treatment promptly.

Although uncommon, some patients may experience minor skin reactions, such as rash or itching, while using fezonatant. These reactions are usually mild, but in rare cases if a reaction is severe, patients should stop taking the medication and seek medical advice.

In rare cases, some patients may experience neurological-related adverse reactions such as dizziness, fatigue, or insomnia. Although these side effects are uncommon, if the symptoms significantly affect the patient's daily life, it is recommended to discuss adjusting the medication regimen with a doctor.

Fezonatant has no obvious hematological side effects in clinical application, but for some specific patients, mild leukopenia or changes in other blood indicators may occur after using this drug. Hematologic monitoring may be a necessary step during treatment, especially in those patients with preexisting conditions.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c